Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | FPR3 | P25089 | 3/20 | 0.41 |
| ▸ | FPR2 | P25090 | 3/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915559 | 0.85 | KMT2A (0.52) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL18908773 | 0.85 | KMT2A (0.52) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL21451154 | 0.82 | KMT2A (0.49) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL4548019 | 0.82 | KMT2A (0.61) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL9167791 | 0.82 | KMT2A (0.60) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL26452488 | 0.81 | KMT2A (0.53) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL17428293 | 0.80 | KMT2A (0.58) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL5654310 | 0.80 | KMT2A (0.62) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL12009838 | 0.79 | KMT2A (0.58) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL13853727 | 0.79 | KMT2A (0.59) | KMT2ARAB9AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-9581904-B2 | Photoresist overcoat compositions | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160074431-A1 | Methods and Compositions for Improving Appearance and Formation of Scar Tissue | JOHNSON & JOHNSON CONSUMER INC (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140234250-A1 | Methods and Compositions for Improving Appearance and Formation of Scar Tissue | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074431-A1 | Methods and Compositions for Improving Appearance and Formation of Scar Tissue | COL2A1, COL14A1, CUTA | KMT2A 3578/4885RAB9A 3631/4885KDM4E 872/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | KMT2A 3088/4885RAB9A 1761/4885KDM4E 4440/4885 |
| US-20140234250-A1 | Methods and Compositions for Improving Appearance and Formation of Scar Tissue | COL2A1, COL14A1, CUTA | KMT2A 3578/4885RAB9A 3631/4885KDM4E 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.